“Living with a question mark”: psychosocial experience of Portuguese young adults at risk for hereditary amyloid transthyretin amyloidosis with polyneuropathy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
“Living with a question mark”: psychosocial experience of Portuguese young adults at risk for hereditary amyloid transthyretin amyloidosis with polyneuropathy ; volume:15 ; number:4 ; day:8 ; month:7 ; year:2024 ; pages:401-411 ; date:8.2024
Journal of community genetics ; 15, Heft 4 (8.7.2024), 401-411, 8.2024
- Creator
-
Pereira, José D.
Costa, Catarina
Santos, Andreia
Lemos, Marina
Sequeiros, Jorge
Paneque, Milena
Mendes, Álvaro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12687-024-00717-8
- URN
-
urn:nbn:de:101:1-2412012120202.937781262397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
07.03.2025, 9:23 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pereira, José D.
- Costa, Catarina
- Santos, Andreia
- Lemos, Marina
- Sequeiros, Jorge
- Paneque, Milena
- Mendes, Álvaro
- SpringerLink (Online service)
Other Objects (12)
Hereditary transthyretin amyloidosis overview
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy
Hereditary transthyretin amyloidosis: a case report
Altered gut microbiota in Taiwanese A97S predominant transthyretin amyloidosis with polyneuropathy
Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center
Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Hereditary transthyretin amyloidosis overview
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy
Hereditary transthyretin amyloidosis: a case report
Altered gut microbiota in Taiwanese A97S predominant transthyretin amyloidosis with polyneuropathy
Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center
Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Hereditary transthyretin amyloidosis overview
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy
Hereditary transthyretin amyloidosis: a case report
Altered gut microbiota in Taiwanese A97S predominant transthyretin amyloidosis with polyneuropathy
Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center